Download Image
    
Share
  
Post
Brexanolone for COVID-19
1 study with 28 patients
Hospital Icon Control
Hospital Icon Brexanolone Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Brexanolone studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -14% Mortality -14% RCTs -14% Late -14% Favorsbrexanolone Favorscontrol
Jul 27
2022
 Brown et al., NCT04537806 A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19
14% higher mortality (p=1) and no change in progression (p=1). RCT 28 ventilated patients, showing no significant difference with brexanolone treatment.